the JM domain, or activating loop mutations, result in the constitutive activation of FLT3 kinase, which is strongly associated with leukocytosis and poor prognosis in AML patients. Four patients with ITD showed poor treatment response as has been reported. 2 The ITD mutations of AML patients have shown variable rates in other studies. Also our four ITD mutation patients contained the JM domain. However, interestingly, we could not find a D835 mutation in this study, but there were many kinds of duplications at different locations with different sizes.
Some studies have been undertaken on FLT3 mutations in paired samples at diagnosis and relapse and have also shown that the mutation can be unstable and the mutation patterns can change. These studies support the idea that mutations are more likely to represent secondary events during the process of leukemogenesis rather than being primary initiating events. 7, 8 In addition, unlike another report, 8 we found heterogeneous levels of FLT3 expression during chemotherapy at different times in this study (data not shown). In contrast to the ITD mutation, no mutation of D835 was found in patients involved in our experiment, and no patient showed a combination of both ITD mutation and D835 mutation. Refractory AML is heterogeneous and a more complex disease entity and has several clinical characteristics such as a poor response to chemotherapy, a rapid cell cycle, and excessive leukemic proliferation, which are explained by the 'multiple hit theory' or other complex forms of specific gene mutations. Therefore, unlike the optimistic responses to the noble 'target therapy' using STI-571(Glivec R ) in patients with chronic myelogenous leukemia, AML is frequently highly resistant to conventional chemotherapy, and the recently trialed target therapies in patients with FLT3-ITD mutations. Our study demonstrates that various FLT3 mutations in patients with refractory AML may be a factor of poor clinical outcome. Although further aggressive investigation is needed on the exact function and the molecular pathways involved, we suggest that the discovery of these novel mutations may lead us to a highly tailored and more accurate patient stratification. TO THE EDITOR High-dose chemotherapy followed by stem cell rescue has improved the response rate and the overall survival of multiple myeloma patients. However, the disease remains incurable and the majority of the patients develop progressive disease within several years. Treatment options for patients with relapsed or refractory disease are limited. In recent years, thalidomide has been introduced successfully in the treatment of multiple myeloma, yielding an overall response rate of approximately 40%. 1 Here, we report a retrospective analysis of the efficacy and toxicity of thalidomide in multiple myeloma patients with a long-term follow-up.
Between May 1999 and July 2003, 122 patients who had been treated with thalidomide for relapsed or refractory multiple myeloma at five cancer centers in the Netherlands were included in the analysis. The clinical and treatment data of the patients were obtained by means of case research. The median age was 61 years (range 37-85 years), M-protein subtype was IgA in 34, IgG in 74, light chain in 10 patients and four patients had a nonsecretory myeloma. All patients had received one or more prior treatments with chemotherapy. The median number of previous treatments was 3 (range 1-5). A total of 79 patients were treated with conventional chemotherapy, 35 patients had received high-dose melphalan with autologous stem cell rescue and eight patients had received allogeneic stem cell transplantation. Fifteen patients had a soft-tissue plasmacytoma at the onset of treatment with thalidomide. The starting dose and dose escalation of thalidomide was executed to the local hospital regulations. The starting dose of thalidomide was 100 mg/day in 24 patients, 200 mg/day in 96 patients and 400 mg/day in two patients. In 11 of 24 patients at the 100 mg dose and 54 of 96 patients at the 200 mg dose, the thalidomide was escalated to maximum-tolerated dose. The median daily dose of thalidomide was 200 mg (range 50-800 mg) and the 3-month cumulative dose was 18 g.
Response evaluation was based on the criteria of the European Bone Marrow Transplantation Group. Patients, who discontinued treatment before a response could be assessed, were considered to have had no response to treatment. Overall survival (OS) was measured from the date of the start of thalidomide until death. Patients still alive at the date of last contact were censored. The progression-free survival (PFS) of the responders was calculated from the date of response until progression or death, whichever comes first. The National Cancer Institute Common Toxicity Criteria (CTC) were used to grade the nonhematologic adverse effects.
At the time of analysis, 52 of the 122 patients were still alive. The median follow-up from the start of thalidomide treatment was 17.5 months (range 1-42 months). An objective clinical response was observed in 56 patients (46%), that is, complete response in five, partial response in 41 and minimal response in 10 patients. A total of 39 patients (32%) had stable disease and 27 (22%) had progressive disease. The median duration of the responding patients in CR, PR and MR was 21, 10 and 6 months, respectively ( Table 1 ). The median PFS for the responding patients was 10 months. The median overall survival of all patients was 15 months (Figure 1) .
Eight of the 15 patients with soft-tissue plasmacytoma responded to the thalidomide treatment. Four patients had multiple myeloma type IgG, three type IgA and one patient had light-chain myeloma. Two patients had multiple skin nodules and in six patients the plasmacytoma was localized in the chest wall, abdominal, parietal, occipital, orbital and cervical region. Five of the eight patients with reduction of the soft-tissue plasmacytoma had progressive disease within 4 months, two within 7 months and one patient after 10 months.
No relation was found between the response to thalidomide and previous treatment or dose intensity of thalidomide ( Table 2) . Analysis of variables such as age, gender, serum Mcomponent subtype, serum b2 microglobulin, albumin, creatinine and LDH did not show any statistically significant difference in PFS and OS.
In 16 patients with no clinical response to thalidomide alone, dexamethasone was added to the treatment. In eight of the 16 patients, an additional response was observed, that is, five partial response and three minimal response.
The main clinical side effects were somnolence, constipation, peripheral polyneuropathy, dizziness, skin rash and edema (Figure 2 ). Somnolence and constipation were observed in about a quarter of the patients and occurred usually within 10 days. Peripheral polyneuropathy appeared in 36 patients (30%) at 2-8 months after the start of treatment. Seven patients developed a generalized skin rash. Thromboembolic complications were reported in a total of seven patients (6%): four deep vein thrombosis and three pulmonary emboli. The majority of the side effects were low grades, CTC grade 1-2.
Dose reduction of thalidomide was performed in 43 patients (35%) and thalidomide was discontinued in 13 (11%) for reasons of intolerance: nine polyneuropathy, three dizziness and one depression. The majority of the symptoms improved or resolved after dose reduction or discontinuation of thalidomide. OS of 122 patients and PFS of 56 responding patients. From this retrospective analysis in a large group of relapsed or refractory multiple myeloma patients, some important conclusion can be drawn. First, our data of 122 patients with a median follow-up of 17.5 months support those of other studies, which have reported a durable response in approximately 40% of the patients, with median response duration of nearly 1 year. 2, 3 It has been claimed that soft-tissue plasmacytoma has a low probability of response to thalidomide treatment. 4, 5 Incidentally, successful thalidomide treatment of extramedullary myeloma lesions has been reported. 6, 7 In our series, we had eight of the 15 patients with soft-tissue plasmacytoma responded to thalidomide, which does not differ from multiple myeloma in general. However, the duration of response in these patients was short compared with that of those without extramedullary involvement (median 4 vs 10 months).
The observed incidence of thromboembolic complications in this group of patients was 6% when thalidomide was given as a single agent. The incidence is low and comparable with studies of myeloma treated with chemotherapy. 8 Therefore, we do not recommend prophylactic anticoagulation in patients receiving thalidomide as a single agent.
Finally, polyneuropathy was observed in 30% of our patients, which is higher than the incidence described in the literature (15-20%). 2, 3 This higher incidence may reflect that our study group was unselected for age, protocol restrictions or institution. Therefore, this analysis may represent the effects of thalidomide in the general population of myeloma patients. 
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